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Remote superficial femoral artery endarterectomy
and distal aSpire stenting: Multicenter medium-
term results
David Rosenthal, MD,a John D. Martin, MD,b Peter J. Schubart, MD,c Eric D. Wellons, MD,a Frederick
W. Shuler, MD,a and Adam B. Levitt, MD,a Atlanta, Ga; Annapolis, Md; and San Jose, Calif
Objective: The purpose of this study was to examine the results of remote superficial femoral artery endarterectomy
(RSFAE) in conjunction with distal aSpire stenting.
Methods: RSFAE is a minimally invasive procedure performed through a limited groin incision. Forty patients were
included in the study. The indications for the procedure were claudication in 36 patients and limb salvage in 4 patients.
RSFAE was performed with the MollRing Cutter device through a femoral arteriotomy. The distal atheromatous plaque
was “tacked” with the aSpire stent, which is an expandable polytetrafluoroethylene-covered nitinol stent with high radial
strength, yet is flexible and able to withstand compressive forces proximal to the knee joint. Before stent deployment, if
the stent position is not optimal it can be wrapped down, repositioned, and re-expanded. Therefore, not only is the plaque
end point tacked, but the collateral vessels may be preserved. All patients underwent follow-up examination with serial
color-flow ultrasound scanning.
Results: The mean length of endarterectomized superficial femoral artery was 26.2 cm  6.2 cm (range, 13-41 cm). The
primary cumulative patency rate by means of life table analysis was 68.6%  13.5% (SE) at 18 months (mean, 13.2
months; range, 1-31 months). During follow-up percutaneous transluminal balloon or stent angioplasty was necessary in
6 patients, for a primary assisted patency rate of 88.5%  8.5% at 18 months. The locations of recurrent stenoses after
RSFAE were evenly distributed along the endarterectomized artery. There were no deaths and one wound complication,
and mean hospital length of stay was only 2.1  0.5 days.
Conclusions: RSFAE with distal aSpire stenting is a safe and moderately durable procedure. If long-term patency rates are
similar to those of above-knee femoropopliteal bypass graft, this procedure may prove to be a minimally invasive adjunct
for the treatment of superficial femoral artery occlusive disease. (J Vasc Surg 2004;40:67-72.)The treatment of long segment (15 cm) superficial
femoral artery (SFA) occlusive disease with minimally inva-
sive endovascular procedures, such as percutaneous trans-
luminal angioplasty (PTA),1,2 laser-assisted balloon angio-
plasty,3 and atherectomy,4 has proved disappointing, and
the use of stents in concert with long segment angioplasty
has not altered long-term patency.5,6
In 1947 the Portuguese surgeon Cid Dos Santos7
reported the first successful femoral endarterectomy per-
formed through two arteriotomies. Despite early promising
results, SFA endarterectomy was gradually abandoned
when published reports suggested inferior results com-
pared with saphenous vein femoropopliteal bypass.8,9 In
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doi:10.1016/j.jvs.2004.03.0381993, however, two reports advocated a semiclosed endar-
terectomy technique in which a ring stripper was used to
achieve patency rates similar to those of above-knee femo-
ropopliteal (AKFP) endarterectomy.10,11 This operation
required two incisions, but it averted use of prosthetic graft
materials and could be performed in the absence of saphe-
nous vein or preserved the saphenous vein for subsequent
Fig 1. aSpire stent.67
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lution of the “remote” SFA endarterectomy (RSFAE) tech-
nique,12 an operation was available that could be per-
formed through a single incision, enabled debulking of
arterial plaque, and enabled placement of an endovascular
stent. The aSpire stent (Vascular Architects; Fig 1) is an
expandable polytetrafluoroethylene (ePTFE)–covered niti-
nol stent that is flexible, yet has enough high radial strength
to withstand torsional stresses proximal to the knee joint.
After the stent is across the endarterectomy end point it can
be adjusted for diameter and length; if the stent is not in
satisfactory position, for example, covering a collateral ves-
sel, it can be repositioned by “wrapping” it back down to a
low profile and re-expanded, thereby, it is hoped, preserv-
ing major geniculate collateral vessels at the distal end
point.
The purpose of this study was to examine the medium-
term results of RSFAE and aSpire stent placement in a
retrospective multicenter trial.
METHODS
Between October 2000 and July 2003, 47 patients
underwent RSFAE and distal aSpire stenting as part of a
retrospective multicenter study. All patients had docu-
Fig 2. A, Arteriogram obtained after remote superficial
endarterectomy end point. B, aSpire balloon stent ang
preserved.
Table I. Cumulative primary patency rates for remote supe
Interval
(mo)
No. of
grafts at
risk
No. of
grafts
failed
Lost to
follow-up
0–3 40 1 6
3–6 33 3 5
6–9 25 0 8
9–12 17 0 6
12–15 11 1 5
15–18 8 1 0mented SFA occlusions greater than 13 cm long (Trial of
Angioplasty and Stents in Canada C) and were candidates
for revascularization procedures. RSFAE was selected when
the proximal popliteal artery was larger than 4 mm in
diameter. The study centers and respective numbers of
RSFAEs were as follows: Atlanta Medical Center, Atlanta,
Ga (n 8); Anne Arundel Medical Center, Annapolis, Md
(n 22); and O’Conner Hospital, San Jose, Calif (n 10).
The indications for operation were assessed with the “sug-
gested standards for reports dealing with lower extremity
ischemia” by Rutherford et al.12 The indications for oper-
ation were claudication in 36 patients and limb salvage in 4
patients. Twenty-eight patients were men, and mean pa-
tient age was 64.3 years (range, 43-78 years). Eighteen
patients (45.0%) had a history of cigarette smoking, 17
(42.5%) had hypertension, 16 (40.0%) had diabetes melli-
tus, and 13 (32.5%) had coronary artery disease.
The technique of RSFAE with the MollRing Cutter
(Vascular Architects) has been described.13 In summary,
the SFA is exposed through a small groin incision; the
common and proximal profunda femoral arteries may be
exposed as well, if an open endarterectomy is deemed
necessary. After systemic heparinization, an arteriotomy is
made from the origin of the SFA distally, and endarterec-
ral artery endarterectomy. Note distal “plaque shelf” at
ty. C, Completion arteriogram shows collateral vessels
al femoral artery endarterectomy procedures
Total
withdrawn
Interval
patency
rate (%)
Cumulative
patency
rate (%) SE
7 98.3 97.4 0
8 90.1 88.4 2.9
8 100.0 88.4 5.4
6 100.0 88.4 5.4
6 90.1 80.0 5.4
1 87.5 68.6 9.4femo
ioplasrfici
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The intimal core is transversely cut at the SFA origin and
threaded into the loop of a conventional ring stripper
(Vollmar Dissector Aesculap). The size of the ring stripper
and MollRing Cutter are determined by measuring the
diameter of the endarterectomized plaque within the SFA
arteriotomy. Under fluoroscopic surveillance the ring strip-
per is advanced distally down the SFA in a gentle, slow,
rotating fashion beyond the occluded segment, the loca-
tion of which was determined at intraoperative arteriogra-
phy. The ring stripper is exchanged for the MollRing
Cutter device, which transects the distal atheromatous core
under fluoroscopic surveillance. The entire column of
plaque is removed, and arteriography is performed to con-
firm a patent femoropopliteal segment (Fig 2).
Under fluoroscopic guidance a guide wire is passed
across the distal SFA endarterectomy end point, and bal-
loon angioplasty with aSpire stent implantation is per-
formed, “tacking up” the distal plaque to prevent further
dissection (Fig 1). Completion arteriography is performed
to verify RSFAE patency and identify any loose debris,
which can be removed with a Fogarty embolectomy or graft
thrombectomy catheter (Edwards Life Sciences, Vascular
Division). As indicated, the arteriotomy may be extended
proximally to perform open endarterectomy of the com-
mon femoral artery or profunda femoris ostia. Before dis-
charge, 26 patients began taking Plavix 75 mg, and 14
patients began taking a baby aspirin once daily.
All patients underwent clinical evaluation during the
30-day postoperative period. In general, patients were fol-
lowed up at 3, 6, and 12 months, and at 6-month intervals
thereafter, with color-flow duplex ultrasound scanning and
ankle-brachial indexes. Recurrent stenosis was considered
significant if peak systolic velocity was greater than 300
cm/s or the velocity ratio was greater than 3.4. RSFAE
patency was confirmed with duplex scanning or arterio-
graphic evaluation, and the primary end points were occlu-
sion or intervention. Cumulative primary and assisted pri-
mary patency rates were calculated with the actuarial life
table method, based on the number of procedures per-
formed (Table I). Because the study was retrospective, all
statistical analyses must be guarded.
RESULTS
Forty-seven patients underwent RSFAE. In four pa-
tients the guide wire could not be passed across the popli-
teal plaque end point, and the procedure was abandoned.
In three other patients heavily calcified plaque in the SFA
prevented passage of the ring stripper. These patients were
excluded from the study, and underwent uneventful AKFP
bypass grafting at the same anesthesia.
Therefore, the study group consisted of 40 patients
who underwent RSFAE. The indications for surgery (Soci-
ety for Vascular Surgery/International Society for Cardio-
vascular Surgery–North America criteria) were chronic
lower extremity ischemia category 1 to 3 in 36 patients and
category 4 to 5 in 4 patients. Mean length of endarterecto-
mized SFAs was 26.2 cm (range, 13-41 cm). In 8 patientsa common femoral and profunda femoris endarterectomy
was performed also. Completion arteriograms demon-
strated SFA thrombus or fractured plaque in 4 patients,
which was successfully removed with a balloon embolec-
tomy catheter. Two other patients had extravasation of
contrast medium at completion arteriography, but this was
self-limiting and required no intervention. Twenty-six ar-
teriotomies (65.0%) were closed with patch angioplasty (9
with autogenous vein, 16 with prosthetic patch material).
All stents were placed at the endarterectomy end point
across the residual popliteal plaque. Forty-six stents were
placed in 40 patients; 29 stents were 6 mm in diameter by 5
cm long, and 17 were 7 mm in diameter by 5 cm long.
The primary cumulative patency rate by means of life
table analysis was 68.6% 13.5% (SE) at 18 months (mean,
13.2 months; range, 1-31 months; Table I; Fig 3). Repeat
radiologic intervention was necessary in six patients (PTA,
4; stent angioplasty, 2), for a primary assisted patency rate
of 88.5%  8.5% at 18 months (Fig 2; Table II). The
locations of stenoses after RSFAE included two over the
course of the SFA, two at the adductor canal, and two at the
distal stent. Four patients in whom RSFAE failed under-
went AKFP. One above-knee amputation was performed
during follow-up in an elderly patient with diabetes who
had gangrene of the foot. There were no deaths; one
wound complication occurred (skin edge slough); and
mean hospital length of stay was 2.1  0.5 days. The
ankle-brachial index rose from 0.58  0.14 preoperatively
to 0.95  0.04 postoperatively.
DISCUSSION
RSFAE and distal aSpire stenting of the popliteal artery
offers the vascular surgeon a minimally invasive endovascu-
lar alternative for treatment of SFA occlusive disease. The
treatment of long segment (15 cm) SFA occlusive disease
with PTA, PTA with stent angioplasty, laser-assisted bal-
loon angioplasty, or atherectomy has yielded disappointing
Fig 3. Cumulative primary and primary assisted patency after
remote superficial femoral artery endarterectomy.
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SFA endarterectomy in the hope that debulking of the SFA
would improve durability. They reported a 5-year second-
ary patency rate of 61% in 259 SFA endarterectomies and
used a ring stripper, introduced through arteriotomies at
the common femoral and above-knee popliteal arteries to
perform the endarterectomy; the distal popliteal artery
plaque was tacked up with sutures. However, plaque frac-
tures during ring stripper endarterectomy resulted in in-
complete removal of SFA plaque, which led to early failure.
The development by Ho et al13 of a remote endarterectomy
technique, performed through a single incision in combi-
nation with distal plaque balloon or stent angioplasty,
assisted in complete removal of the SFA plaque and simpli-
fied treatment of the distal end point. This technique
offered several advantages: it was minimally invasive, a
second distal incision was averted, a common femoral and
profunda femoris endarterectomy could be easily per-
formed, it averted use of prosthetic material, and it could be
performed in the absence of saphenous vein or preserved
Table II. Cumulative primary assisted patency rates for rem
Interval
(mo)
No. of
grafts at
risk
No. of
grafts
failed
Lost to
follow-up
0–3 40 0 5
3–6 35 1 5
6–9 29 0 6
9–12 23 0 5
12–15 18 1 5
15–18 12 0 1
Fig 4. Arteriogram obtained after aSpirthe saphenous vein for subsequent cardiovascular or pe-
ripheral reconstructions. RSFAE has been performed with a
variety of stents across the residual popliteal plaque, and
recurrent stenosis rates have ranged from 20% to 46% at
follow-up extending to 24 months.13-15
In this study, after RSFAE the distal atheromatous
plaque was tacked with the aSpire stent, which has a nitinol
framework that provides greater wall coverage, and its
ePTFE covering eliminates metal to artery contact, one of
the possible causes of neointimal hyperplasia. It is flexible,
yet has high radial strength to withstand torsional stresses
proximal to those of the knee joint, and because of its
unique design facilitates laminar flow (Fig 4) (T. Wei,
personal communication, 2003).16 By adjusting the posi-
tion of the stent spiral before final deployment, not only are
the plaque and end point tacked, but the geniculate collat-
eral vessels at the end point are preserved as well. The
12-month (88.4%) and 18-month (68.6%) primary cumu-
lative patency rates achieved in this study are similar to
those reported by Ho et al17 and more recently by Smeets
superficial femoral artery endarterectomy procedures
Total
withdrawn
Interval
patency
rate (%)
Cumulative
patency
rate (%) SE
5 100 100 0
6 97.1 96.5 0
6 100 96.5 3.5
5 100 96.5 3.5
6 94.4 88.5 8.5
1 100 88.5 8.5
t angioplasty with patient’s knee flexed.otee sten
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bypass grafting.19 Ho et al20 in another report described
“relining” the artery after RSFAE with an endoluminal
ePTFE graft to prevent recurrent stenosis, but the patency
rate at 12 months for this endograft procedure was only
69.7%, and it was abandoned. The incidence of stenosis
after RSFAE remains significant in that 15% of patients (6
of 40) required an adjunctive procedure (PTA, 4; stent
angioplasty, 2) to maintain SFA patency. Although the
incidence of early (2 years) stenosis in this study (15%)
was less than that reported by Rosenthal et al21 (23%), Ho
et al17 (46%), or Smeets et al18 (25%), it may not be
statistically different. Nevertheless, recurrent stenosis due
to intimal hyperplasia remains the Achilles heel of RSFAE
and is of concern. It is hoped that in the near future the use
of improved anti-platelet medications or drug therapy, or
endothelial cell seeding or brachytherapy will help resolve
the problem of recurrent stenosis. Of interest is the obser-
vation that in four patients with failed RSFAE, symptoms
were less severe than before the operation. This was
thought to be a function of collateral vessels being
opened at endarterectomy; however, this remains to be
proved.
The treatment of femoropopliteal occlusive disease
with RSFAE in combination with distal aSpire popliteal
stent angioplasty continues to evolve. In a previous study16
we used various self-expanding stents after RSFAE at the
endarterectomy end point, and recurrent stenosis occurred
in 23% of patients. The management of the end point
remains a concern, but the aSpire stent ePTFE covering
prevents metal to artery contact, which may decrease inti-
mal hyperplasia. In addition, the stent design enables col-
lateral vessel preservation, which may improve patency as
well, but further studies are necessary to validate this. It is
hoped that development of new endarterectomy instru-
ments, such as the Schubart periscope and Martin dissector
(Drs P. Schubart and J. Martin, personal communication,
2003), which facilitate endarterectomy as well as guide wire
passage, in concert with the aSpire stent, will improve
durability of this procedure. Long segment SFA occlusive
disease has not been successfully treated with radiologic
minimally invasive procedures, because of length of the
SFA, its small caliber, and relatively low flow. It is incum-
bent on the vascular surgeon therefore to develop a mini-
mally invasive superior alternative. Recanalization of the
SFA with a guide wire, laser, or atherectomy in combina-
tion with PTA ultimately leads to arterial recoil and remod-
eling. This may cause arterial collapse or place significant
external compression on any endograft, owing to the nat-
ural tendency of the arterial wall after dilation. Debulking
of the artery appears to reduce arterial recoil and remodel-
ing,22,23 and it is hoped that RSFAE will offer patients a
procedure of comparable morbidity, but with more du-
rable patency rates, similar to those of AKFP bypass
grafting.
RSFAE with distal aSpire stenting is a safe and moder-
ately durable procedure that enables preservation of SFA
collateral vessels. If long-term patency rates are similar tothose of AKFP bypass grafting, RSFAE may prove to be a
minimally invasive adjunct for the treatment of SFA occlu-
sive disease.
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Submitted Jan 5, 2004; accepted Mar 23, 2004.DISCUSSIONDr Alan Lumsden (Houston, Tex). This is a retrospective
review of a multicenter study. Thirty-four patients with claudica-
tion and 4 patients with limb-threatening ischemia were treated.
The study evaluates the combined efficacy of 2 components:
remote endarterectomy and the use of the Aspire stent. The
endarterectomies were long, averaging 25.8 cms in length, and the
ability to complete this endarterectomy is a reflection on the
efficacy of the Moll ring cutter. In only a small portion of the
endarterectomized segments, the end point was covered with the
Aspire device. Results are surprisingly good given the length of the
endarterectomized segment: primary patency of 69.8% at 13
months. The Aspire stent graft is unique in its double helical nitinol
backbone, and is only partially covered with ePTFE. It is also
unique in the ability to control length of the stent deployment and
as a consequence of the amount of wall coverage.
I have several questions for Dr Rosenthal and coauthors. First,
although the length of the device can be controlled at the time of
deployment, thereby varying the length of the covered segment,
was this clinically useful and how often did you readjust to preserve
large collaterals. Second, ePTFE can be loaded with drug. Are
there any plans to use this device as a drug delivery platform? Third,
how important do you think a stent graft is, versus a stent for the
end point? Fourth, there is increasing concern about the mechan-
ical stresses exerted upon stents that approximate the knee joint,
and do you advocate placing a stent beyond the adductor canal?
Dr David Rosenthal. In response to the first question, the
stent was “rewrapped” in approximately one quarter to one third
of cases, as we wanted to preserve the large collaterals you men-
tioned. This is one of the major benefits of the aSpire stent in
concert with remote endarterectomy.
PTFE can be loaded with drugs, and there will most certainly
be adjuncts on the horizon to hopefully improve patency of this
procedure. Obviously, gene manipulation, hemorheologic medi-
cations, radiation, and drug-eluting stents all may play a role in
improving this procedure.
Third, I think the use of a stent graft versus the aSpire stent
may be self-defeating in that a stent graft would “tack” the distal
plaque, but you would lose the all-important collateral side
branches.
The concerns about the mechanical stresses at the knee joint
are real. As you are well aware, the extrinsic compression, rotation,
and flexion forces upon a stent at the knee joint do occur, buthopefully, with the aSpire stents’ unique configuration, these will
be reduced.
Dr F. Noel Parent (Virginia Beach, Va). I have just started to
use this instrument, and I have noted some trouble with a curled
end point. Do you have any tricks to provide as to how to deal with
that? We have just gone ahead and gone to subintimal angioplasty
at that point, and then we break through distally when it feathers
and place the stent there. Do you do that?
And do you have any suggestions about working through an
old above-knee popliteal anastomotic site? Does that provide any
difficulties to you?
Have you had any perforations, and what is your bailout?
Dr Rosenthal. Your questions about technical difficulties are
appropriate. The 2 most difficult steps of this procedure are getting
the guide wire to cross the end point and simplifying the endarter-
ectomy. After we do the endarterectomy, getting the guide wire to
cross the distal end point can be frustrating, but there are a couple
of adjuncts you can try. Passing a balloon catheter just to the edge
of the plaques shelf and expanding the balloon opens the plaque
edges at the end point that may have been “kissing.” This allows
passage of the guide wire. As far as simplifying the endarterectomy,
industry is trying to develop new instrumentation for the proce-
dure. John Martin and Peter Schubart, who are coauthors in this
study, both have dissectors that assist in dissection and allow you to
pass a guide wire. We are also working on a new cutting device that
would look like the Volmar stripper and have a recessed stainless
steel wire in the head, so that when you get to the end point, the
wire simply cuts the plaque sharply, like a garrote. This will make
remote SFA endarterectomy a 1-step procedure and, by cutting the
plaque sharply, will allow easier guide wire passage.
Your second question was, if you have a failed popliteal
anastomosis after an above-knee femoropopliteal bypass, can you
do this procedure? I tried it once, and the obvious problem is the
suture material in the artery at the popliteal anastomosis. I could
not pass this end point and it is probably not appropriate.
Your last question had to do with perforations and what my
bailout is. Perforations with remote endarterectomy have, thank-
fully, been self-limiting. By this, I mean that with repeat arteriog-
raphy the contrast extravasation disappears. Certainly, if I had a
continued extravasation, I would either cover it with a stent graft,
if it was immediately available, or repair it surgically.
